Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Ana...
August 06 2020 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a
dedicated biologics contract development and manufacturing
organization (CDMO) working to improve patient lives by providing
high quality development and manufacturing services to
biotechnology and pharmaceutical companies, today announced that
Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide
process development, pilot-batch manufacturing and CGMP
manufacturing services to support development of IOV-3001, a novel
antibody cytokine engrafted protein.
Cell line development activities for IOV-3001
are currently being conducted by Aragen Bioscience under a
subcontracting agreement with Avid. In parallel with cell line
development, Avid will commence analytical activities, upstream and
downstream process development, and pilot-scale non-GMP
manufacturing for IOV-3001. Following completion of these
activities, Avid will advance to CGMP manufacturing of IOV-3001
within Avid’s state-of-the-art Myford facility in Tustin, CA.
“We are pleased to be selected by Iovance to
provide CDMO services to support the company’s continued
advancement in developing novel anti-cancer drug candidates. As an
Interleukin-2/antibody engrafted protein, IOV-3001 is the type of
complex therapeutic candidate for which Avid possesses unique
process development and manufacturing expertise, illustrated by our
27 years of producing related compounds,” said Timothy
Compton, chief commercial officer of Avid. “This new contract award
also illustrates the value of Avid’s efforts to establish alliances
with key providers of complementary CDMO services such as Aragen.
We are pleased to have them contribute their cell line development
expertise to this project.”
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical drug
substances derived from mammalian cell culture. The company
provides a comprehensive range of process development, CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 27 years of
experience producing monoclonal antibodies and recombinant
proteins, Avid's services include CGMP clinical and commercial drug
substance manufacturing, bulk packaging, release and stability
testing and regulatory submissions support. For early-stage
programs the company provides a variety of process development
activities, including upstream and downstream development and
optimization, analytical methods development, testing and
characterization. The scope of our services ranges from standalone
process development projects to full development and manufacturing
programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024